CIK 0000818686 · Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- operating
- Phone
- 972 (3) 914-8213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,923,078
- in 11 filings, $11.2M under 10b5-1 plans
Net −$33,923,078. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-05 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Option exercise · Restricted Share Units | −21,390 | 0 | ||
| 2025-03-05 | Kalif Eliyahu Sharon EVP, Chief Financial Officer | Grant or award · Restricted Share Units | +79,664 | 79,664 | ||
| 2025-03-05 | Hughes Eric A See "Remarks" | Grant or award · Restricted Share Units | +78,616 | 78,616 | ||
| 2025-03-05 | Sabag Mark See "Remarks" | Option exercise | +23,765 | 488,911 | ||
| 2025-03-05 | Sabag Mark See "Remarks" | Option exercise · Restricted Share Units | −23,765 | 0 | ||
| 2025-03-05 | Sabag Mark See "Remarks" | Grant or award · Restricted Share Units | +62,893 | 62,893 | ||
| 2025-03-05 | Shields Matthew EVP, Global Operations | Grant or award · Restricted Share Units | +69,182 | 69,182 | ||
| 2025-03-05 | Jover Placid See "Remarks" | Grant or award · Restricted Share Units | +56,603 | 56,603 | ||
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Option exercise 10b5-1 | +22,576 | 119,345 | ||
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −22,576 | $15.91 | $359K | 96,769 |
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −48,385 | $15.90 | $769K | 48,384 |
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units 10b5-1 | −22,576 | 0 | ||
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Grant or award · Restricted Share Units 10b5-1 | +69,182 | 69,182 | ||
| 2025-03-05 | Francis Richard D President and CEO | Grant or award · Restricted Share Units | +169,811 | 169,811 | ||
| 2025-03-05 | Fox Christine EVP, Head of U.S. Commercial | Sale 10b5-1 | −2,147 | $15.91 | $34K | 58,384 |
| 2025-03-05 | McAvoy David R. EVP, Chief Legal Officer | Sale 10b5-1 | −1,677 | $15.91 | $27K | 11,914 |
| 2025-03-05 | Hughes Eric A See "Remarks" | Sale 10b5-1 | −8,077 | $15.91 | $129K | 0 |
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −11,641 | $15.91 | $185K | 0 |
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −7,108 | $15.91 | $113K | 0 |
| 2025-03-05 | Daniell Richard Exec. VP, European Commercial | Sale 10b5-1 | −30,015 | $15.91 | $478K | 96,769 |
Page 15 of 76 · 1,517 trades